Circassia Pharmaceuticals PLC (LON:CIR)‘s stock had its “neutral” rating reiterated by J P Morgan Chase & Co in a report issued on Friday.

Separately, Numis Securities Ltd restated a “buy” rating and issued a GBX 180 ($2.32) price target on shares of Circassia Pharmaceuticals PLC in a research report on Thursday.

Shares of Circassia Pharmaceuticals PLC (LON:CIR) traded up 1.15% on Friday, hitting GBX 88.00. The stock had a trading volume of 445,469 shares. The stock has a 50 day moving average price of GBX 87.64 and a 200-day moving average price of GBX 91.99. The company’s market cap is GBX 250.47 million. Circassia Pharmaceuticals PLC has a 12-month low of GBX 76.75 and a 12-month high of GBX 114.00.

TRADEMARK VIOLATION WARNING: “J P Morgan Chase & Co Reiterates Neutral Rating for Circassia Pharmaceuticals PLC (CIR)” was first published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and reposted in violation of US and international trademark and copyright legislation. The correct version of this report can be viewed at

Circassia Pharmaceuticals PLC Company Profile

Circassia Pharmaceuticals plc is a specialty biopharmaceutical company focused on allergy and respiratory diseases. The Company operates through three segments: Allergy, which relates to a range of immunotherapy development products for the treatment of allergy; NIOX, which relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO), and Respiratory, which relates to the portfolio of asthma and chronic obstructive pulmonary disease product candidates.

Receive News & Ratings for Circassia Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Circassia Pharmaceuticals PLC and related companies with's FREE daily email newsletter.